Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

86P - Phyllodes tumours: understanding more about the unknown.

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Soomin Jang

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101218-101218. 10.1016/esmoop/esmoop101218

Authors

Y. Aung1, A. Bouhelal2, S. Jang1, K. Weigel1, L. Begolli2

Author affiliations

  • 1 The Royal London Hospital, London/GB
  • 2 King George Hospital, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 86P

Background

Phyllodes tumours (PT), comprising <1% of breast tumours, are rare fibroepithelial lesions ranging from benign to malignant. Although their excision is generally recommended, there is still no consensus on optimal PT management. This study thus aimed to better delineate the course and management of PT through our 15-year experience at a breast surgery unit.

Methods

This was a retrospective single-center study of patients with histologically proven PT from 2005-2021. Data regarding demographics, presentation, investigations, management, and follow-up were extracted, and were statistically analysed using R.

Results

101 cases were identified, comprising 79 benign, 15 borderline and 7 malignant PT. Mean age was 39.7±17.0 years, and patients with malignant PT were significantly older (p=0.039). All patients presented with masses, 52.5% affecting the left breast. On triple assessment, higher clinical scores (p=0.008) and biopsy scores (p<0.001) were associated with malignancy, however ultrasound and mammogram scores were not. Biopsy histology was available for 98.9% of patients, of which 35.6% did not suspect PT on initial biopsy as they were predominantly believed to be fibroadenomas (84.4%). 93.1% underwent wide local excision (WLE), and 6.9% underwent mastectomies. The nearest excision margin was stated in 37.2% after WLE; however, only 5.7% were above the recommended 1cm, and 40.4% had positive margins. Mean margins were highest in malignant PT (p=0.054). Subsequently, 43.6% underwent margin excision, and 2 patients with malignant PT underwent mastectomy. Mean follow-up period was 29.4±35.2 months, with significantly longer FU in malignant PT (p<0.001). Recurrence rate was 12.9% overall, comprising 12 benign PT cases recurring as 8 benign, 2 borderline and 2 malignant PT, as well as 1 borderline PT recurrence. Survival was 92.4%, with no record of metastases.

Conclusions

Although rare and variable in disease course, comprehensive guidelines are needed in managing PT. In particular, further research is warranted into optimal excision margins and follow-up given the difficulty differentiating between benign fibroadenoma and early PT, and the risk of upgrading PT on recurrence.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.